Clinical Trial Update: Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 study assesses potential drug-drug interactions when the three-drug hepatitis C antiviral combination (daclatasvir/asunaprevir/BMS-791325) is coadm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• DIGOXIN (Digoxin)
• Daclatasvir (daclatasvir)
• Pravastatin (pravastatin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED